DeepMind's AlphaGenome ships with non-commercial terms
DeepMind released AlphaGenome Atlas, described as a high-resolution map of human DNA with 2,234 selectable body part meshes and detailed genomic annotation. The thread immediately flagged the terms of service: non-commercial use only, which blocks most drug discovery startups from building directly on top of it. This is the same pattern as AlphaFold's initial release, where the research was open but the commercial path ran through DeepMind.
One commenter noted the irony dryly: the same company whose other atlas still routes you into a lake is now mapping the human genome. But the more substantive point is that DeepMind is systematically producing foundational biological AI research that it releases publicly while reserving commercial rights. That's a specific competitive strategy, not an oversight.
For biotech founders, this creates a two-tier world: academic and nonprofit researchers can use the best tools freely, while commercial developers either pay DeepMind or build on inferior alternatives.
So what?
If you're building in biotech or genomics, read the ToS on every DeepMind release before building a workflow dependency on it. The pattern of open research with closed commercial terms is consistent enough that you should assume it until proven otherwise. Build your own fine-tuned alternatives or negotiate commercial access early.